We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Valeant Pharmaceuticals’ application for a latanoprostene bunod eye solution was rejected by the FDA amid concerns about conditions at the company’s manufacturing facilities. Read More
The European Medicines Agency is recommending halting sales of 136 drugs whose approval came from flawed bioequivalence studies performed at the Semler Research Centre in India. Read More
Xellia Pharmaceuticals and the FDA have agreed on a modified consent decree so Xellia can resume manufacturing at the Bedford, Ohio, site it purchased from Ben Venue Laboratories. Read More
The FDA has approved a new drug co-developed by Valeant Pharmaceuticals and Progenics Pharmaceuticals that treats opioid-induced constipation in adults. Read More